Horizon Therapeutics plc Announces Plans to Expand its Development and Manufacturing Facility in Waterford, IrelandBusiness Wire • 08/29/22
Horizon Therapeutics plc to Present at the Morgan Stanley 20th Annual Global Healthcare ConferenceBusiness Wire • 08/25/22
New Contender Viridian Takes Aim At Horizon's Eye Drug, And RocketsInvestors Business Daily • 08/15/22
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune DiseasesBusiness Wire • 08/15/22
Horizon Therapeutics Public Limited Company (HZNP) CEO Tim Walbert on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/03/22
Horizon Therapeutics (HZNP) Q2 Earnings and Revenues Lag EstimatesZacks Investment Research • 08/03/22
Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA GuidanceBusiness Wire • 08/03/22
Why Horizon Therapeutics (HZNP) Might Surprise This Earnings SeasonZacks Investment Research • 08/02/22
Can Horizon Therapeutics (HZNP) Keep the Earnings Surprise Streak Alive?Zacks Investment Research • 07/28/22
Horizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant RecipientsBusiness Wire • 07/21/22
Horizon Therapeutics plc Announces Wanda Durant Has Joined Olympian Gail Devers to Raise Awareness of Thyroid Eye Disease Among Graves' Disease CommunityBusiness Wire • 07/11/22
FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to TherapyBusiness Wire • 07/08/22
Horizon Therapeutics plc to Release Second-Quarter 2022 Financial Results and Host Webcast on Aug. 3, 2022Business Wire • 07/07/22
New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)Business Wire • 06/24/22
Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in BrazilBusiness Wire • 06/15/22
Horizon Therapeutics plc Named One of the Fortune Best Workplaces in Chicago™Business Wire • 06/15/22
Analysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED)Business Wire • 06/11/22